Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients

Gillis, Ryan D.; Botteri, Edoardo; Chang, Aeson; Ziegler, Alexandra I.; Chung, Ni Chun; Pon, Cindy K.; Shackleford, David M.; Andreassen, Bettina K.; Halls, Michelle L.; Baker, Jillian G.; Sloan, Erica K.

doi:10.1016/j.ejca.2021.01.029

All Outputs (2)

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors (2021)
Journal Article
Proudman, R. G. W., & Baker, J. G. (2021). The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors. Pharmacology Research and Perspectives, 9(4), Article e00799. https://doi.org/10.1002/prp2.799

Highly selective drugs offer a way to minimize side-effects. For agonist ligands, this could be through highly selective affinity or highly selective efficacy, but this requires careful measurements of intrinsic efficacy. The α1-adrenoceptors are imp... Read More about The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors.

Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients (2021)
Journal Article
Gillis, R. D., Botteri, E., Chang, A., Ziegler, A. I., Chung, N. C., Pon, C. K., …Sloan, E. K. (2021). Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. European Journal of Cancer, 147, 106-116. https://doi.org/10.1016/j.ejca.2021.01.029

© 2021 Elsevier Ltd Purpose: The sympathetic nervous system drives breast cancer progression through β-adrenergic receptor signalling. This discovery has led to the consideration of cardiac β-blocker drugs as novel strategies for anticancer therapi... Read More about Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.